183 related articles for article (PubMed ID: 36610823)
1. Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes.
Chaumont H; Kaczorowski F; San-Galli A; Michel PP; Tressières B; Roze E; Quadrio I; Lannuzel A
Rev Neurol (Paris); 2023 Mar; 179(3):208-217. PubMed ID: 36610823
[TBL] [Abstract][Full Text] [Related]
2. Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms.
Edén A; Grahn A; Bremell D; Aghvanyan A; Bathala P; Fuchs D; Gostner J; Hagberg L; Kanberg N; Kanjananimmanont S; Lindh M; Misaghian S; Nilsson S; Schöll M; Sigal G; Stentoft E; Studahl M; Yilmaz A; Wang M; Stengelin M; Zetterberg H; Gisslén M
JAMA Netw Open; 2022 May; 5(5):e2213253. PubMed ID: 35604688
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid analysis in patients with COVID-19-associated central nervous system manifestations: a systematic review.
Domingues RB; Leite FBVM; Senne C
Arq Neuropsiquiatr; 2022 Mar; 80(3):296-305. PubMed ID: 35239818
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity.
Virhammar J; Nääs A; Fällmar D; Cunningham JL; Klang A; Ashton NJ; Jackmann S; Westman G; Frithiof R; Blennow K; Zetterberg H; Kumlien E; Rostami E
Eur J Neurol; 2021 Oct; 28(10):3324-3331. PubMed ID: 33369818
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development.
Espíndola OM; Brandão CO; Gomes YCP; Siqueira M; Soares CN; Lima MASD; Leite ACCB; Torezani G; Araujo AQC; Silva MTT
Int J Infect Dis; 2021 Jan; 102():155-162. PubMed ID: 33127503
[TBL] [Abstract][Full Text] [Related]
6. CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome.
Guasp M; Muñoz-Sánchez G; Martínez-Hernández E; Santana D; Carbayo Á; Naranjo L; Bolós U; Framil M; Saiz A; Balasa M; Ruiz-García R; Sánchez-Valle R;
Front Immunol; 2022; 13():866153. PubMed ID: 35479062
[TBL] [Abstract][Full Text] [Related]
7. CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series.
Edén A; Kanberg N; Gostner J; Fuchs D; Hagberg L; Andersson LM; Lindh M; Price RW; Zetterberg H; Gisslén M
Neurology; 2021 Jan; 96(2):e294-e300. PubMed ID: 33004602
[TBL] [Abstract][Full Text] [Related]
8. Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes.
Paterson RW; Benjamin LA; Mehta PR; Brown RL; Athauda D; Ashton NJ; Leckey CA; Ziff OJ; Heaney J; Heslegrave AJ; Benedet AL; Blennow K; Checkley AM; Houlihan CF; Mummery CJ; Lunn MP; Manji H; Zandi MS; Keddie S; Chou M; Vinayan Changaradil D; Solomon T; Keshavan A; Barker S; Jäger HR; Carletti F; Simister R; Werring DJ; Spyer MJ; Nastouli E; Gauthier S; Rosa-Neto P; ; Zetterberg H; Schott JM
Brain Commun; 2021; 3(3):fcab099. PubMed ID: 34396099
[TBL] [Abstract][Full Text] [Related]
9. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses.
Pilotto A; Masciocchi S; Volonghi I; De Giuli V; Caprioli F; Mariotto S; Ferrari S; Bozzetti S; Imarisio A; Risi B; Premi E; Benussi A; Focà E; Castelli F; Zanusso G; Monaco S; Stefanelli P; Gasparotti R; Zekeridou A; McKeon A; Ashton NJ; BlennoW K; Zetterberg H; Padovani A
Clin Infect Dis; 2021 Nov; 73(9):e3019-e3026. PubMed ID: 33395482
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm.
Garcia MA; Barreras PV; Lewis A; Pinilla G; Sokoll LJ; Kickler T; Mostafa H; Caturegli M; Moghekar A; Fitzgerald KC; ; Pardo CA
J Neurol Sci; 2021 Aug; 427():117517. PubMed ID: 34090021
[TBL] [Abstract][Full Text] [Related]
12. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations.
Bonetto V; Pasetto L; Lisi I; Carbonara M; Zangari R; Ferrari E; Punzi V; Luotti S; Bottino N; Biagianti B; Moglia C; Fuda G; Gualtierotti R; Blasi F; Canetta C; Montano N; Tettamanti M; Camera G; Grimoldi M; Negro G; Rifino N; Calvo A; Brambilla P; Biroli F; Bandera A; Nobili A; Stocchetti N; Sessa M; Zanier ER
Front Immunol; 2022; 13():1070379. PubMed ID: 36591311
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum and cerebrospinal fluid biomarkers after vaccination against SARS-CoV-2.
Iacono S; Piccoli T; Aridon P; Schirò G; Blandino V; Tarantino D; Agnello L; Ciaccio M; Ragonese P; Salemi G
Ann Clin Transl Neurol; 2023 Jun; 10(6):1025-1034. PubMed ID: 37139906
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis.
Rajda C; Galla Z; Polyák H; Maróti Z; Babarczy K; Pukoli D; Vécsei L
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290514
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of hospitalized NeuroCOVID diagnoses from a tertiary care neurology centre in Eastern India.
Bhansali S; Bagrodia V; Choudhury S; Rahman S; Golder M; Tiwari M; Kumar H
J Clin Neurosci; 2021 Nov; 93():96-102. PubMed ID: 34656269
[TBL] [Abstract][Full Text] [Related]
16. Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.
Souza FDS; Freitas NL; Gomes YCP; Torres RC; Echevarria-Lima J; da Silva-Filho IL; Leite ACCB; de Lima MASD; da Silva MTT; Araújo AQC; Espíndola OM
Front Immunol; 2021; 12():737941. PubMed ID: 34764955
[TBL] [Abstract][Full Text] [Related]
17. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis.
Mariotto S; Gajofatto A; Zuliani L; Zoccarato M; Gastaldi M; Franciotta D; Cantalupo G; Piardi F; Polo A; Alberti D; Sartori S; Zanusso G; Agrò L; Demurtas R; Sechi G; Sechi E; Monaco S; Ferrari S
J Neurol; 2019 Jul; 266(7):1643-1648. PubMed ID: 30944980
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients.
Alexopoulos H; Magira E; Bitzogli K; Kafasi N; Vlachoyiannopoulos P; Tzioufas A; Kotanidou A; Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32978291
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients.
Lersy F; Benotmane I; Helms J; Collange O; Schenck M; Brisset JC; Chammas A; Willaume T; Lefebvre N; Solis M; Hansmann Y; Fabacher T; Caillard S; Mertes PM; Pottecher J; Schneider F; Meziani F; Fafi-Kremer S; Kremer S
J Infect Dis; 2021 Feb; 223(4):600-609. PubMed ID: 33249438
[TBL] [Abstract][Full Text] [Related]
20. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium.
Chou SH; Beghi E; Helbok R; Moro E; Sampson J; Altamirano V; Mainali S; Bassetti C; Suarez JI; McNett M;
JAMA Netw Open; 2021 May; 4(5):e2112131. PubMed ID: 33974053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
